Swedish Orphan Biovitrum AB/ SE0000872095 /
| 5/22/2024 7:57:24 AM | Chg. -0.1000 | Volume | Bid2:48:40 PM | Ask2:48:40 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 24.0000EUR | -0.41% | - Turnover: - |
23.8200Bid Size: 470 | 23.8400Ask Size: 470 | 8.45 bill.EUR | - | - |
GlobeNewswire
5/15
ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at ...
GlobeNewswire
5/9
ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
GlobeNewswire
5/6
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire
5/6
ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLON...
GlobeNewswire
5/1
ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on...
GlobeNewswire
4/4
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination wit...
GlobeNewswire
4/3
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
GlobeNewswire
3/13
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business U...
GlobeNewswire
3/6
ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit
GlobeNewswire
3/6
ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March...
GlobeNewswire
3/5
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cance...
GlobeNewswire
12/12/2023
ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evalua...
GlobeNewswire
11/7/2023
ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards
GlobeNewswire
11/7/2023
ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
GlobeNewswire
11/6/2023
Health Canada Approves DOPTELET (avatrombopag) for Two Indications in Thrombocytopenia
GlobeNewswire
11/6/2023
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
GlobeNewswire
11/2/2023
Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies fo...
GlobeNewswire
11/2/2023
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting
GlobeNewswire
11/1/2023
Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer
GlobeNewswire
10/31/2023
Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Comme...
GlobeNewswire
10/24/2023
ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023
